title: Topical application of integrin antagonists inhibits proliferative retinopathy.
abstract: The expression of alphav-integrins is highly selective for angiogenic endothelial cells; ligation inhibition by cyclic RGD peptides prevents pathological neovascularization in tumor or retinopathy models to a large extent. We have previously demonstrated that proliferative retinopathy in a mouse model of retinopathy of prematurity (ROP model) can be reduced by more than 70%. To minimize systemic side effects and unwanted interference with responsive angiogenesis, we investigated topical application of cyclic RGD-peptides. In preliminary experiments, we could exclude any inhibiting effects of the carrier solution containing EDTA, Na2S, mannitol, hydroxyethyl starch, and benzalconium chloride on the inhibitory effect of cyclic RGD peptides. Retinal presence of small molecular-mass integrin antagonists after topical application was confirmed using fluorescein-labeled cyclic RGD peptide. Topical application of the peptide to the eye inhibited proliferative retinopathy in a dose-dependent fashion with a maximum of almost 50%. These results suggest that small molecular-mass peptide antagonists of alphav-type integrins are efficient in inhibiting proliferative retinopathy by topical application.
authors: 3rd Medical Department, Justus-Liebig-University Giessen, Germany.
authors: B
authors: B
authors: Riecke
authors: E
authors: E
authors: Chavakis
authors: R G
authors: RG
authors: Bretzel
authors: T
authors: T
authors: Linn
authors: K T
authors: KT
authors: Preissner
authors: M
authors: M
authors: Brownlee
authors: H P
authors: HP
authors: Hammes
mesh_terms: D000268:Adhesiveness; D000287:Administration, Topical; D000818:Animals; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D000860:Hypoxia / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000473:pathology; D009842:Oligopeptides / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D009883:Ophthalmic Solutions; D019030:Receptors, Vitronectin / Q000037:antagonists & inhibitors*; D012160:Retina / Q000378:metabolism
chemical_list: D009842:Oligopeptides; D009883:Ophthalmic Solutions; D019030:Receptors, Vitronectin; C047981:arginyl-glycyl-aspartic acid